CLIA Guidance Draws Industry Criticism On User Comparability Studies
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking waived status for diagnostic tests should be able to choose a statistically appropriate sample for user comparability tests, according to comments submitted by industry on FDA's March 1 draft guidance on criteria for CLIA waiver applications.
You may also be interested in...
HHS Sign-Off Critical To CLIA Waiver Proposal: FDA Criteria At Odds With CMS'
Manufacturers seeking CLIA waivers for in vitro diagnostics should wait until FDA's interim guidance is finalized before using the alternative approach it outlines, according to CDRH.
HHS Sign-Off Critical To CLIA Waiver Proposal: FDA Criteria At Odds With CMS'
Manufacturers seeking CLIA waivers for in vitro diagnostics should wait until FDA's interim guidance is finalized before using the alternative approach it outlines, according to CDRH.
CLIA Guidance Allows Firms To Gain Waiver Through User Comparison Studies
Manufacturers seeking waived status for diagnostic tests under user-based criteria will need to perform agreement studies with at least 300 untrained users to show that those users obtain the same results as lab professionals, according to an FDA draft guidance issued Jan. 23.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: